Glucocorticoid receptor polymorphism, skin vasoconstriction, and other metabolic intermediate phenotypes in normal human subjects

Journal of Clinical Endocrinology and Metabolism

Volumn 83, Issue 6, 1998, Pages 1846-1852

  Panarelli, Maurizio ^a   Holloway, Christine D ^b   Fraser, Robert ^b   Connell, John M C ^b   Ingram, Mary C ^b   Anderson, Niall H ^b   Kenyon, Christopher J ^c  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^b WESTERN INFIRMARY   (United Kingdom)

^c WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; BUDESONIDE; CHOLESTEROL; DEXAMETHASONE; GLUCOCORTICOID RECEPTOR; HYDROCORTISONE; LYSOZYME; STEROID; STEROID 5ALPHA REDUCTASE; STEROID 5BETA REDUCTASE; TETRAHYDROCORTISOL; TETRAHYDROCORTISONE;

ADULT; ARTICLE; BLOOD PRESSURE; BODY FAT; CONTROLLED STUDY; GENE LOCUS; GENETIC LINKAGE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HETEROZYGOTE; HOMOZYGOTE; HORMONE RECEPTOR INTERACTION; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; LIPID METABOLISM; MALE; NORMAL HUMAN; PHENOTYPE; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SKIN BLOOD VESSEL; STEROID METABOLISM; VASOCONSTRICTION;

ADIPOSE TISSUE; ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; ALLELES; BLOOD PRESSURE; BODY COMPOSITION; BODY MASS INDEX; DEOXYRIBONUCLEASES, TYPE II SITE-SPECIFIC; GENOTYPE; HUMANS; MALE; PHENOTYPE; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RECEPTORS, GLUCOCORTICOID; REGRESSION ANALYSIS; SKIN; VASOCONSTRICTION;

EID: 0031732980     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.83.6.1846     Document Type: Article

References (46)

1. Arai K, Chrousos GP. 1994 Glucocorticoid resistance. Baillieres Clin Endocrinol Metab. 8:317-331.
2. Panarelli M, Fraser R. 1994 The glucocorticoid receptor and hypertension. Endocr Res. 20:101-116.
3. Murray JC, Smith RF, Ardinger HA, Weinberg C. 1987 RFLP for the glucocorticoid receptor (GR) located at 5q11-5q13. Nucleic Acids Res. 15:6765.
4. Watt GCM, Harrap SB, Foy CJW, et al. 1992 Abnormalities of glucocorticoid metabolism and the renin-angiotension system: a four corners approach to the identification of the genetic determinants of blood pressure. J Hypertens. 10:473-482.
5. Weaver JU, Hitman GA, Kopelman PG. 1992 An association between Bcl 1 restriction fragment length polymorphism of the glucocorticoid receptor locus and hyperinsulinaemia in obese women. J Mol Endocrinol. 9:295-300.
6. Stamler R, Stamler J, Riedlinger WF, Algera G, Roberts RH. 1978 Weight and blood pressure JAMA. 240:1607-1610.
7. Martinez FJ, Sancho-Rof JM. 1993 Epidemiology of high blood pressure and obesity. Drugs. 46[Suppl 2]:160-164.
8. Place VA, Velasquez JG, Burdick KH. 1970 Precise evaluation of topically applied corticosteroid potency. Modification of the Stoughton-Mckenzie assay. Arch Dermatol. 101:531-537.
9. Kenyon CJ, Morton JJ. 1994 Experimental steroid-induced hypertension. In: Swales JD, ed. Textbook of hypertension. Oxford: Blackwell Scientific Publ.; 494-500.
10. Vingerhoeds ACM, Thijssen JHH, Schwartz FJ. 1976 Spontaneous hypercortisolism without Cushing's syndrome. J Clin Endocrinol Metab. 43:1128-1133.
11. Chrousos GP, Vingerhoed A, Brandon DD, et al. 1982 Primary cortisol resistance in man. A glucocorticoid receptor-mediated disease. J Clin Invest. 69:1261-1269.
12. Edwards CRW, Burt D, McIntyre MA, et al. 1988 Localization of 11 beta-hydroxysteroid dehydrogenase-tissue specific protector of the mineralocorticoid receptor. Lancet. ii:986-989.
13. Funder JW, Pearce PT, Smith R, Smith AL. 1988 Mineralocorticoid action: target tissue specificity is enzyme not receptor mediated. Science. 242:583-585.
14. Jamieson PM, Chapman KE, Edwards CRW, Seckl JR. 1995 11β-Hydroxysteroid dehydrogenase is an exclusive 11β-reductase in primary cultures of rat hepatocytes: effect of physicochemical and hormonal manipulations. Endocrinology. 136:4754-4761.
15. Walker BR, Connacher AA, Lindsay RM, Webb DJ, Edwards CRW. 1995 Carbenoxolone increases hepatic insulin sensitivity in man: a novel role for 11β-oxosteroid reductase in enhancing glucocorticoid receptor activation. J Clin Endocrinol Metab. 80:3155-3159.
16. Zuti W, Golding L. 1973 Equations for estimating percent fat and body density of active adult males. Med Sci Sport. 5:262-267.
17. Teelucksingh S, Mackie ADR, Burt D, McIntyre MA, Brett LP, Edwards CRW. 1990 Potentiation of hydrocortisone activity in skin by glycyrrhetinic acid. Lancet. 335:1060-1063.
18. Panarelli M, Holloway CD, Mulatero P, Fraser R, Kenyon CJ. 1994 Inhibition of lysozyme synthesis by dexamethasone in human mononuclear leukocytes: an index of glucocorticoid sensitivity. J Clin Endocrinol Metab. 78:872-877.
19. Munson PJ, Rodbard D. 1980 Ligand: versatile computerised approach for characterisation of ligand-binding systems. Anal Biochem. 107:220-239.
20. Miller SA, Dykes DD, Polesky HF. 1988 A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 16:12115.
21. Bingham AH, Atkinson T, Sciaky D, Roberts RJ. 1978 A specific endonuclease from bacillus caldolyticus. Nucleic Acids Res. 5:3457-3467.
22. Hollenberg SM, Weinberg C, Ong ES, et al. 1985 Primary structure and expression of a functional human glucocorticoid receptor cDNA. Nature. 318:635-641.
23. Millar J, Leckie BJ, Morton JJ, Tree M. 1978 A microassay for active and total renin concentration in human plasma based on antibody trapping. Clin Chim Acta. 101:5-15.
24. Soro A, Ingram MC, Tonolo G, Glorioso N, Fraser R. 1995 Evidence of coexisting changes in 11β-hydroxysteroid dehydrogenase and 5β-reductase activity in subjects with untreated essential hypertension. Hypertension. 25:67-70.
25. Nobukuni Y, Smith CL, Hager GL, Detera-Wadleigh SD. 1995 Characterization of the human glucocorticoid receptor promoter. Biochemistry. 34:8207-8214.
26. Bamberger CM, Bamberger A-M, de Castro M, Chrousos GP. 1995 Glucocorticoid receptor β, a potential endogenous inhibitor of glucocorticoid action in humans. J Clin Invest. 95:2435-2441.
27. Oakley RH, Sar M, Cidlowski JA. 1996 The human glucocorticoid receptor beta isoform. Expression, biochemical properties, and putative function. J Biol Chem. 271:9550-9559.
28. Werner S, Brönnegård M. 1996 Molecular basis of glucocorticoid-resistant syndromes. Steroids. 61:216-221.
29. Chrousos GP, Detera-Wadleigh SD, Karl M. 1993 Syndromes of glucocorticoid resistance. Ann Int Med. 119:1113-1124.
30. Molijn GJ, Spek JJ, Van Uffelen JCJ, et al. 1995 Differential adaptation of glucocorticoid sensitivity of peripheral blood mononuclear leukocytes in patients with sepsis or septic shock. J Clin Endocrinol Metab. 80:1799-1803.
31. Leung DYM, Szefler SJ. 1997 Diagnosis and management of steroid-resistant asthma. Clin Chest Med. 18:611-625.
32. Horwitz KB, Jackson TA, Bain DL, Richer JK, Takimoto GS, Tung TL. 1996 Nuclear coactivators and corepressors. Mol Endocrinol. 10:1167-1177.
33. Adcock IM, Lane SJ, Brown CR, Lee TH, Barnes PJ. 1995 Abnormal glu-cocorticoid receptor-activator protein 1 interaction in steroid-resistant asthma. J Exp Med. 182:1951-1958.
34. Burns K, Duggan B, Atkinson EA, et al. 1994 Modulation of gene expression by calreticulin binding to the glucocorticoid receptor. Nature. 367:476-480.
35. Kamei Y, Xu L, Heinzel T, et al. 1996 A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell. 85:403-414.
36. Stocklin E, Wissler M, Gouilleux F, Groner B. 1996 Functional interactions between Stat5 and the glucocorticoid receptor. Nature. 383:726-728.
37. De Lange P, Koper JW, Huizenga NATM, et al. 1997 Differential hormone-dependent transcriptional activation and -repression by naturally occurring human glucocorticoid receptor variants. Mol Endocrinol. 11:1156-1164.
38. Komel L, Starnes WR, Hill SR, Hill A. 1969 Studies on steroid conjugates, VI: Quantitative paper chromatography of urinary corticosteroids in essential hypertension. J Clin Endocrinol Metab. 29:1608-1617.
39. Latif SA, Conca TJ, Morris DJ. 1990 The effects of the liquorice derivative, glycyrrhetinic acid, on hepatic 3α-and 3β-hydroxysteroid dehydrogenase and 5α-and 5β-reductase pathways of aldosterone in male rats. Steroids. 55:52-58.
40. Ulick S, Tedde R, New M. 1992 Defective ring A reduction of cortisol as a major metabolic error in the syndrome of apparent mineralocorticoid excess. J Clin Endocrinol Metab. 74:593-599.
41. Ulick S, Wang JZ, Hanukoglu A, Rosier A. 1993 The effect of carbenoxolone on the peripheral metabolism of cortisol in human patients. J Lab Clin Med. 122:673-676.
42. Walker BR, Best R, Shackleton CHL, Padfield PL, Edwards CRW. 1996 Increased vasoconstrictor sensitivity to glucocorticoids in essential hypertension. Hypertension. 27:190-196.
43. Lamberts SWJ, Koper JW, Biemond P, den Holder FH, de Jong FH. 1992 Cortisol receptor resistance: the variability of its clinical presentation and response to treatment. J Clin Endocrinol Metab. 74:313-321.
44. Malchoff CD, Malchoff DM. 1995 Clucocorticoid resistance in humans. Trends Endocrinol Metab. 6:89-95.
45. Walker BR, Noon JP, Panarelli M, et al. 1995 Sensitivity to glucocorticoids predicts predisposition to hypertension. J Endocrinol. 147[Suppl]:P9.
46. Clement K, Philippi A, Jury C, et al. 1996 Candidate gene approach of familial morbid obesity: linkage analysis of the glucocorticoid receptor gene. Int J Obes Rel Metab Dis. 20:507-512.